β-adrenergic receptor signalling and its functional consequences in the diseased heart

European Journal of Clinical Investigation

Volumn 46, Issue 4, 2016, Pages 362-374

  Najafi, Aref ^a,b   Sequeira, Vasco ^a   Kuster, Diederik W D ^a   van der Velden, Jolanda ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

Author keywords

A kinase anchoring protein (AKAP); Heart failure; Hypertrophic cardiomyopathy; Protein kinase A (PKA); adrenergic receptor

Indexed keywords

ALPRENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; IVABRADINE; LEVOSIMENDAN; METOPROLOL; NEBIVOLOL; OMECAMTIV MECARBIL; PROTEIN KINASE C;

ADRENERGIC STIMULATION; DESENSITIZATION; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEART PROTECTION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC); CARDIOMYOPATHY, HYPERTROPHIC; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

CARDIOMYOPATHY, HYPERTROPHIC; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEART FAILURE; HUMANS; PHOSPHORYLATION; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 84975770251     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12598     Document Type: Review

References (131)

1. Bers DM. Cardiac excitation-contraction coupling. Nature 2002;415:198-205.
2. Baker AJ. Adrenergic signaling in heart failure: a balance of toxic and protective effects. Pflugers Arch 2014;466:1139-50.
3. Richardson DW, Kontos HA, Raper AJ, Patterson JL Jr. Modification by beta-adrenergic blockade of the circulatory responses to acute hypoxia in man. J Clin Invest 1967;46:77-85.
4. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT et al. The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci USA 2003;100:4903-8.
5. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002;415:206-12.
6. Madamanchi A. Beta-adrenergic receptor signaling in cardiac function and heart failure. Mcgill J Med 2007;10:99-104.
7. Cannavo A, Liccardo D, Koch WJ. Targeting cardiac beta-adrenergic signaling via GRK2 inhibition for heart failure therapy. Front Physiol 2013;4:264.
8. Moniotte S, Kobzik L, Feron O, Trochu JN, Gauthier C, Balligand JL. Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 2001;103:1649-55.
9. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
10. Lefkowitz RJ. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 1998;273:18677-80.
11. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 1999;100:2210-2.
12. Balligand JL. Beta3-adrenoreceptors in cardiovasular diseases: new roles for an "old" receptor. Curr Drug Deliv 2013;10:64-6.
13. Xiang Y, Kobilka BK. Myocyte adrenoceptor signaling pathways. Science 2003;300:1530-2.
14. Reddy YS. Phosphorylation of cardiac regulatory proteins by cyclic AMP-dependent protein kinase. Am J Physiol 1976;231:1330-6.
15. Sutherland EW, Rall TW. Formation of adenosine-3, 5-phosphate (cyclic adenylate) and its relation to the action of several neurohormones or hormones. Acta Endocrinol Suppl (Copenh) 1960;34(Suppl 50):171-4.
16. Wattanapermpool J, Guo X, Solaro RJ. The unique amino-terminal peptide of cardiac troponin I regulates myofibrillar activity only when it isphosphorylated. J Mol Cell Cardiol 1995;27:1383-91.
17. Kuster DW, Bawazeer AC, Zaremba R, Goebel M, Boontje NM, van der Velden J. Cardiac myosin binding protein C phosphorylation in cardiac disease. J Muscle Res Cell Motil 2012;33:43-52.
18. Stelzer JE, Patel JR, Walker JW, Moss RL. Differential roles of cardiac myosin-binding protein C and cardiac troponin I in the myofibrillar force responses to protein kinase A phosphorylation. Circ Res 2007;101:503-11.
19. Yamasaki R, Wu Y, McNabb M, Greaser M, Labeit S, Granzier H. Protein kinase A phosphorylates titin's cardiac-specific N2B domain and reduces passive tension in rat cardiac myocytes. Circ Res 2002;90:1181-8.
20. Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996;79:1059-63.
21. Ginsburg KS, Bers DM. Modulation of excitation-contraction coupling by isoproterenol in cardiomyocytes with controlled SR Ca2 + load and Ca2 + current trigger. J Physiol 2004;556:463-80.
22. van der Heyden MA, Wijnhoven TJ, Opthof T. Molecular aspects of adrenergic modulation of cardiac L-type Ca2 + channels. Cardiovasc Res 2005;65:28-39.
23. Haj Slimane Z, Bedioune I, Lechene P, Varin A, Lefebvre F, Mateo P et al. Control of cytoplasmic and nuclear protein kinase A by phosphodiesterases and phosphatases in cardiac myocytes. Cardiovasc Res 2013;102:97-106.
24. Ruehr ML, Russell MA, Bond M. A-kinase anchoring protein targeting of protein kinase A in the heart. J Mol Cell Cardiol 2004;37:653-65.
25. Diviani D, Maric D, Perez Lopez I, Cavin S, Del Vescovo CD. A-kinase anchoring proteins: molecular regulators of the cardiac stress response. Biochim Biophys Acta 2013;1833:901-8.
26. Skroblin P, Grossmann S, Schafer G, Rosenthal W, Klussmann E. Mechanisms of protein kinase A anchoring. Int Rev Cell Mol Biol 2010;283:235-330.
27. Di Benedetto G, Zoccarato A, Lissandron V, Terrin A, Li X, Houslay MD et al. Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ Res 2008;103:836-44.
28. Barradeau S, Imaizumi-Scherrer T, Weiss MC, Faust DM. Intracellular targeting of the type-I alpha regulatory subunit of cAMP-dependent protein kinase. Trends Cardiovasc Med 2002;12:235-41.
29. Dostmann WR, Taylor SS. Identifying the molecular switches that determine whether (Rp)-cAMPS functions as an antagonist or an agonist in the activation of cAMP-dependent protein kinase I. Biochemistry 1991;30:8710-6.
30. Xiang YK. Compartmentalization of beta-adrenergic signals in cardiomyocytes. Circ Res 2011;109:231-44.
31. Stangherlin A, Gesellchen F, Zoccarato A, Terrin A, Fields LA, Berrera M et al. cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ Res 2011;108:929-39.
32. Bers DM, Ziolo MT. When is cAMP not cAMP? Effects of compartmentalization Circ Res 2001;89:373-5.
33. Lygren B, Carlson CR, Santamaria K, Lissandron V, McSorley T, Litzenberg J et al. AKAP complex regulates Ca2 + re-uptake into heart sarcoplasmic reticulum. EMBO Rep 2007;8:1061-7.
34. Sumandea CA, Garcia-Cazarin ML, Bozio CH, Sievert GA, Balke CW, Sumandea MP. Cardiac troponin T, a sarcomeric AKAP, tethers protein kinase A at the myofilaments. J Biol Chem 2011;286:530-41.
35. Uys GM, Ramburan A, Loos B, Kinnear CJ, Korkie LJ, Mouton J et al. Myomegalin is a novel A-kinase anchoring protein involved in the phosphorylation of cardiac myosin binding protein C. BMC Cell Biol 2011;12:18.
36. Hundsrucker C, Klussmann E. Direct AKAP-mediated protein-protein interactions as potential drug targets. Handb Exp Pharmacol 2008;2008:483-503.
37. Dessauer CW. Adenylyl cyclase-A-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol Pharmacol 2009;76:935-41.
38. Brum PC, Rolim NP, Bacurau AV, Medeiros A. Neurohumoral activation in heart failure: the role of adrenergic receptors. An Acad Bras Cienc 2006;78:485-503.
39. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
40. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003;93:896-906.
41. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978;41:233-43.
42. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998;98:1329-34.
43. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
44. Eschenhagen T. Beta-adrenergic signaling in heart failure-adapt or die. Nat Med 2008;14:485-7.
45. Benovic JL, Strasser RH, Caron MG, Lefkowitz RJ. Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc Natl Acad Sci USA 1986;83:2797-801.
46. Rockman HA, Choi DJ, Rahman NU, Akhter SA, Lefkowitz RJ, Koch WJ. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci USA 1996;93:9954-9.
47. Freedman NJ, Lefkowitz RJ. Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 2004;113:1379-82.
48. Tobin AB. G-protein-coupled receptor phosphorylation: where, when and by whom. Br J Pharmacol 2008;153(Suppl 1):S167-76.
49. Penn RB, Panettieri RA Jr, Benovic JL. Mechanisms of acute desensitization of the beta2AR-adenylyl cyclase pathway in human airway smooth muscle. Am J Respir Cell Mol Biol 1998;19:338-48.
50. Strasser RH, Benovic JL, Caron MG, Lefkowitz RJ. Beta-agonist- and prostaglandin E1-induced translocation of the beta-adrenergic receptor kinase: evidence that the kinase may act on multiple adenylate cyclase-coupled receptors. Proc Natl Acad Sci USA 1986;83:6362-6.
51. Belmonte SL, Blaxall BC. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res 2011;109:309-19.
52. Dorn GW 2nd. GRK mythology: G-protein receptor kinases in cardiovascular disease. J Mol Med (Berl) 2009;87:455-63.
53. Penela P, Murga C, Ribas C, Tutor AS, Peregrin S, Mayor F Jr. Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc Res 2006;69:46-56.
54. Jaber M, Koch WJ, Rockman H, Smith B, Bond RA, Sulik KK et al. Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. Proc Natl Acad Sci USA 1996;93:12974-9.
55. Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol 2003;63:9-18.
56. Iaccarino G, Rockman HA, Shotwell KF, Tomhave ED, Koch WJ. Myocardial overexpression of GRK3 in transgenic mice: evidence for in vivo selectivity of GRKs. Am J Physiol 1998;275:H1298-306.
57. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005;308:512-7.
58. Shenoy SK, Lefkowitz RJ. beta-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 2011;32:521-33.
59. Krueger KM, Daaka Y, Pitcher JA, Lefkowitz RJ. The role of sequestration in G protein-coupled receptor resensitization. Regulation of beta2-adrenergic receptor dephosphorylation by vesicular acidification. J Biol Chem 1997;272:5-8.
60. Claing A, Laporte SA, Caron MG, Lefkowitz RJ. Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 2002;66:61-79.
61. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993;87:454-63.
62. Zakhary DR, Moravec CS, Stewart RW, Bond M. Protein kinase A (PKA)-dependent troponin-I phosphorylation and PKA regulatory subunits are decreased in human dilated cardiomyopathy. Circulation 1999;99:505-10.
63. Dell'Acqua ML, Scott JD. Protein kinase A anchoring. J Biol Chem 1997;272:12881-4.
64. Aye TT, Soni S, van Veen TA, van der Heyden MA, Cappadona S, Varro A et al. Reorganized PKA-AKAP associations in the failing human heart. J Mol Cell Cardiol 2012;52:511-8.
65. Schwinger RH, Munch G, Bolck B, Karczewski P, Krause EG, Erdmann E. Reduced Ca(2 + )-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol 1999;31:479-91.
66. Mehel H, Emons J, Vettel C, Wittkopper K, Seppelt D, Dewenter M et al. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes. J Am Coll Cardiol 2013;62:1596-606.
67. Champion HC. Targeting protein phosphatase 1 in heart failure. Circ Res 2005;96:708-10.
68. Huang KX, Paudel HK. Ser67-phosphorylated inhibitor 1 is a potent protein phosphatase 1 inhibitor. Proc Natl Acad Sci USA 2000;97:5824-9.
69. El-Armouche A, Pamminger T, Ditz D, Zolk O, Eschenhagen T. Decreased protein and phosphorylation level of the protein phosphatase inhibitor-1 in failing human hearts. Cardiovasc Res 2004;61:87-93.
70. van Bilsen M, van Nieuwenhoven FA, van der Vusse GJ. Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res 2009;81:420-8.
71. Opie LH, Thandroyen FT, Muller C, Bricknell OL. Adrenaline-induced "oxygen-wastage" and enzyme release from working rat heart. Effects of calcium antagonism, beta-blockade, nicotinic acid and coronary artery ligation. J Mol Cell Cardiol 1979;11:1073-94.
72. van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardiovasc Res 2004;61:218-26.
73. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002;40:271-7.
74. Song X, Zheng X, Malbon CC, Wang H. Galpha i2 enhances in vivo activation of and insulin signaling to GLUT4. J Biol Chem 2001;276:34651-8.
75. Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X et al. Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature 2009;457:1146-9.
76. Cipolletta E, Campanile A, Santulli G, Sanzari E, Leosco D, Campiglia P et al. The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance. Cardiovasc Res 2009;84:407-15.
77. Ciccarelli M, Santulli G, Pascale V, Trimarco B, Iaccarino G. Adrenergic receptors and metabolism: role in development of cardiovascular disease. Front Physiol 2013;4:265.
78. Fu Q, Xu B, Liu Y, Parikh D, Li J, Li Y et al. Insulin inhibits cardiac contractility by inducing a Gi-biased beta2-adrenergic signaling in hearts. Diabetes 2014;63:2676-89.
79. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997;80:15L-25L.
80. Tsagalou EP, Anastasiou-Nana M, Agapitos E, Gika A, Drakos SG, Terrovitis JV et al. Depressed coronary flow reserve is associated with decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2008;52:1391-8.
81. Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991;40:972-7.
82. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007;116:434-48.
83. Corbi G, Conti V, Russomanno G, Longobardi G, Furgi G, Filippelli A et al. Adrenergic signaling and oxidative stress: a role for sirtuins? Front Physiol 2013;4:324.
84. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-36.
85. Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 2003;9:354-63.
86. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
87. Mansoor AM, Honda M, Kuramochi T, Tanaka K, Morioka S, Takabatake T. Effects of ACE inhibition and beta-blockade on collagen remodelling in the heart of Bio 14.6 hamsters. Clin Exp Pharmacol Physiol 1996;23:43-9.
88. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550-60.
89. Teerlink JR, Massie BM. The role of beta-blockers in preventing sudden death in heart failure. J Card Fail 2000;6:25-33.
90. Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol 1998;21:I3-13.
91. Lechat P. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
92. Yue TL, Wang X, Gu JL, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995;273:1442-9.
93. O'Brien ET. Advantages and disadvantages of beta-adrenergic blocking drugs in hypertension. Angiology 1978;29:332-6.
94. Liang M, Puri A, Devlin G. Heart rate and cardiovascular disease: an alternative to Beta blockers. Cardiol Res Pract 2009;2009:179350.
95. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA 2008;105:14555-60.
96. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 2010;335:572-9.
97. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 2007;104:16657-62.
98. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 2007;117:2445-58.
99. Erickson CE, Gul R, Blessing CP, Nguyen J, Liu T, Pulakat L et al. The beta-blocker Nebivolol Is a GRK/beta-arrestin biased agonist. PLoS ONE 2013;8:e71980.
100. Warne T, Edwards PC, Leslie AG, Tate CG. Crystal structures of a stabilized beta1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 2012;20:841-9.
101. Nobles KN, Xiao K, Ahn S, Shukla AK, Lam CM, Rajagopal S et al. Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Sci Signal 2011;4:ra51.
102. Kim IM, Wang Y, Park KM, Tang Y, Teoh JP, Vinson J et al. beta-arrestin1-biased beta1-adrenergic receptor signaling regulates microRNA processing. Circ Res 2014;114:833-44.
103. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011;331:1439-43.
104. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007;356:1140-51.
105. Boknik P, Neumann J, Kaspareit G, Schmitz W, Scholz H, Vahlensieck U et al. Mechanisms of the contractile effects of levosimendan in the mammalian heart. J Pharmacol Exp Ther 1997;280:277-83.
106. Orstavik O, Ata SH, Riise J, Dahl CP, Andersen GO, Levy FO et al. Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart. Br J Pharmacol 2014;171:5169-81.
107. Mebazaa A, Barraud D, Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol 2005;96:74G-9G.
108. Passino C, Severino S, Poletti R, Piepoli MF, Mammini C, Clerico A et al. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J Am Coll Cardiol 2006;47:1835-9.
109. Lavie CJ, Arena R, Swift DL, Johannsen NM, Sui X, Lee DC et al. Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ Res 2015;117:207-19.
110. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-239.
111. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, Chen W et al. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell 2007;130:247-58.
112. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA 2001;98:5809-14.
113. Rockman HA, Choi DJ, Akhter SA, Jaber M, Giros B, Lefkowitz RJ et al. Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem 1998;273:18180-4.
114. Raake PW, Schlegel P, Ksienzyk J, Reinkober J, Barthelmes J, Schinkel S et al. AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013;34:1437-47.
115. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE et al. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009;119:89-98.
116. Koch WJ, Rockman HA, Samama P, Hamilton RA, Bond RA, Milano CA et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995;268:1350-3.
117. Casey LM, Pistner AR, Belmonte SL, Migdalovich D, Stolpnik O, Nwakanma FE et al. Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure. Circ Res 2010;107:532-9.
118. McConnell BK, Popovic Z, Mal N, Lee K, Bautista J, Forudi F et al. Disruption of protein kinase A interaction with A-kinase-anchoring proteins in the heart in vivo: effects on cardiac contractility, protein kinase A phosphorylation, and troponin I proteolysis. J Biol Chem 2009;284:1583-92.
119. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733-79.
120. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-16.
121. Schumacher C, Becker H, Conrads R, Schotten U, Pott S, Kellinghaus M et al. Hypertrophic cardiomyopathy: a desensitized cardiac beta-adrenergic system in the presence of normal plasma catecholamine concentrations. Naunyn Schmiedebergs Arch Pharmacol 1995;351:398-407.
122. Choudhury L, Guzzetti S, Lefroy DC, Nihoyannopoulos P, McKenna WJ, Oakley CM et al. Myocardial beta adrenoceptors and left ventricular function in hypertrophic cardiomyopathy. Heart 1996;75:50-4.
123. Sequeira V, Wijnker PJ, Nijenkamp LL, Kuster DW, Najafi A, Witjas-Paalberends ER et al. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res 2013;112:1491-505.
124. Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res 2012;97:464-71.
125. Dweck D, Sanchez-Gonzalez MA, Chang AN, Dulce RA, Badger CD, Koutnik AP et al. Long term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathy. J Biol Chem 2014;289:23097-111.
126. Freeman K, Colon-Rivera C, Olsson MC, Moore RL, Weinberger HD, Grupp IL et al. Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene. Am J Physiol Heart Circ Physiol 2001;280:H151-9.
127. Prabhakar R, Boivin GP, Grupp IL, Hoit B, Arteaga G, Solaro RJ et al. A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. J Mol Cell Cardiol 2001;33:1815-28.
128. Borbely A, Falcao-Pires I, van Heerebeek L, Hamdani N, Edes I, Gavina C et al. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009;104:780-6.
129. Sirenko SG, Potter JD, Knollmann BC. Differential effect of troponin T mutations on the inotropic responsiveness of mouse hearts-role of myofilament Ca2 + sensitivity increase. J Physiol 2006;575:201-13.
130. van der Velden J, Papp Z, Zaremba R, Boontje NM, de Jong JW, Owen VJ et al. Increased Ca2 + -sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins. Cardiovasc Res 2003;57:37-47.
131. Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R et al. Targets for therapy in sarcomeric cardiomyopathies. Cardiovasc Res 2015;105:457-70.